Search research articles
Contact Us
Filters
Showing results (1-10 of 19) with videos related to
Page
of 2
Sort By:
Advances in Psychosomatic Medicine
|
April 9, 2008
The impact of physical illness on sexual dysfunction
Anita Clayton, Sujatha Ramamurthy
Sexual Medicine
|
January 3, 2017
What Sexual Behaviors Relate to Decreased Sexual Desire in Women? A Review and Proposal for End Points in Treatment Trials for Hypoactive Sexual Desire Disorder
Robert Pyke, Anita Clayton
Menopause (New York, N.Y.)
|
August 19, 2008
Recognition of depression among women presenting with menopausal symptoms
Anita Clayton, Christine Guico-Pabia
The Journal of Sexual Medicine
|
April 17, 2007
Proposal for changes in diagnostic criteria for sexual dysfunctions
Robert Segraves, Richard Balon, Anita Clayton
Journal of Affective Disorders
|
January 25, 2006
Burden of phase-specific sexual dysfunction with SSRIs
Anita Clayton, Adrienne Keller, Elizabeth L McGarvey
The Journal of Sexual Medicine
|
August 14, 2019
Paroxetine, but not Vortioxetine, Impairs Sexual Functioning Compared With Placebo in Healthy Adults: A Randomized, Controlled Trial
Paula Jacobsen, Wei Zhong, George Nomikos, et al.
The Journal of Sexual Medicine
|
July 14, 2007
Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder
Anita Clayton, Susan Kornstein, Apurva Prakash, et al.
Journal of Clinical Psychopharmacology
|
May 1, 2004
Bupropion sustained release for the treatment of hypoactive sexual desire disorder in premenopausal women
Robert Taylor Segraves, Anita Clayton, Harry Croft, et al.
The Journal of Sexual Medicine
|
November 29, 2007
Validation of the female sexual distress scale-revised for assessing distress in women with hypoactive sexual desire disorder
Leonard Derogatis, Anita Clayton, Diane Lewis-D'Agostino, et al.
Menopause (New York, N.Y.)
|
January 23, 2014
Post hoc analysis of the efficacy and safety of desvenlafaxine 50 mg/day in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder
Susan G Kornstein, Anita Clayton, Weihang Bao, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 19) with videos related to
Sort By:
Page
of 2
Advances in Psychosomatic Medicine
|
April 9, 2008
The impact of physical illness on sexual dysfunction
Anita Clayton, Sujatha Ramamurthy
Sexual Medicine
|
January 3, 2017
What Sexual Behaviors Relate to Decreased Sexual Desire in Women? A Review and Proposal for End Points in Treatment Trials for Hypoactive Sexual Desire Disorder
Robert Pyke, Anita Clayton
Menopause (New York, N.Y.)
|
August 19, 2008
Recognition of depression among women presenting with menopausal symptoms
Anita Clayton, Christine Guico-Pabia
The Journal of Sexual Medicine
|
April 17, 2007
Proposal for changes in diagnostic criteria for sexual dysfunctions
Robert Segraves, Richard Balon, Anita Clayton
Journal of Affective Disorders
|
January 25, 2006
Burden of phase-specific sexual dysfunction with SSRIs
Anita Clayton, Adrienne Keller, Elizabeth L McGarvey
The Journal of Sexual Medicine
|
August 14, 2019
Paroxetine, but not Vortioxetine, Impairs Sexual Functioning Compared With Placebo in Healthy Adults: A Randomized, Controlled Trial
Paula Jacobsen, Wei Zhong, George Nomikos, et al.
The Journal of Sexual Medicine
|
July 14, 2007
Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder
Anita Clayton, Susan Kornstein, Apurva Prakash, et al.
Journal of Clinical Psychopharmacology
|
May 1, 2004
Bupropion sustained release for the treatment of hypoactive sexual desire disorder in premenopausal women
Robert Taylor Segraves, Anita Clayton, Harry Croft, et al.
The Journal of Sexual Medicine
|
November 29, 2007
Validation of the female sexual distress scale-revised for assessing distress in women with hypoactive sexual desire disorder
Leonard Derogatis, Anita Clayton, Diane Lewis-D'Agostino, et al.
Menopause (New York, N.Y.)
|
January 23, 2014
Post hoc analysis of the efficacy and safety of desvenlafaxine 50 mg/day in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder
Susan G Kornstein, Anita Clayton, Weihang Bao, et al.
Page
of 2